Have you ever watched a solid business get cheaper for reasons that had almost nothing to do with customers walking through the door? That is the odd position CVS Group has occupied for a few years. The pets still needed care. The clinics still booked appointments. Earnings still moved forward. The share price, though, spent a long stretch looking over its shoulder at a regulator instead of at the operating numbers.
Why CVS Group Suddenly Looks Cheap Again
I keep coming back to a simple contrast. For much of the past decade, investors were happy to pay a premium for this company because the end market is stubbornly resilient and the growth record is unusually clean. Then the sector review arrived, nerves took over, and the multiple slid toward a ten-year low around 13 times earnings. That kind of rerating can be justified. It can also overshoot. The interesting work is deciding which of those two things happened here.
In my experience, markets love a neat story. A competition inquiry is a neat story. It is also a blunt instrument. While the process dragged on, the group kept adding sites, building specialist capacity, pushing a subscription club, and buying practices in Australia. Revenue did not freeze. Ebitda did not freeze. What froze was the willingness of many investors to look past the headline risk.
Temporary uncertainty can knock a high-quality compounder onto a discount that has little to do with the quality of the cash flows.
That is the setup. Not a miracle stock. Not a distressed wreck either. A veterinary network that spent years under a cloud and now has to be judged on the business itself.
A Market That Does Not Behave Like Other Consumer Spend
Pet care is one of those corners of the economy that refuses to follow the usual household script. People delay a new kitchen. They keep the old car another year. They do not, as a rule, leave a sick animal sitting on the sofa because the budget feels tight that month. Demand is not perfectly recession-proof. Nothing is. It is still far stickier than most discretionary categories.
There is a second layer that matters just as much. Veterinary medicine has become more sophisticated. Treatments that used to live only in a handful of specialist centres now show up more often in everyday practice networks: advanced imaging, orthopaedics, oncology. That shift raises average spend per animal over time. It also rewards groups that already own the referral hospitals and labs rather than sending the work out the door.
Then there is the cohort effect from the pandemic pet boom. Those puppies and kittens are no longer tiny. They are entering the years when routine care turns into more frequent diagnostics and procedures. You do not need a dramatic forecast to see why lifetime spend can keep rising even if new pet ownership cools.
- Owners delay big household purchases more readily than treatment for a sick pet
- More complex medicine lifts the value of each clinical relationship
- Animals acquired during the lockdown years are ageing into higher-spend phases
- Integrated networks keep more of that spend inside one group
Put those pieces together and you get an industry that can grow without needing the economy to feel festive. That backdrop is why this business was rarely cheap in the first place.
From Practice Roll-Up To An Integrated Healthcare Network
CVS Group listed in 2007 and has spent the years since doing something rarer than people admit: growing revenue and Ebitda without a break. Plenty of listed firms talk about compounding. Few actually post an unbroken line through cycles, labour crunches, and a sector inquiry.
The original model was straightforward consolidation. Buy independent clinics, professionalise them, capture scale. That still matters. The more interesting evolution is the shape of the network today. Roughly 500 sites now sit across general practice, referral hospitals, diagnostic laboratories, and an online pharmacy. A first visit for a vaccination can become imaging, surgery, or oncology without the client leaving the group.
That sounds operational. It is also strategic. Referrals that stay inside the network improve utilisation of expensive kit and specialist teams. They raise lifetime value. They make the group more attractive to clinicians who want a career path rather than a single-site ceiling. Scale stops being a slogan and starts behaving like a moat, even if that word gets overused.
I find the loyalty machinery underappreciated. About 500,000 owners pay monthly through The Healthy Pet Club for vaccines, parasite control, and routine checks. Recurring fees are useful on their own. The hidden benefit is frequency. Owners who already have a plan are more likely to walk in, which creates more chances to spot problems early and offer higher-value care. It is not magic. It is habit, packaged as a subscription.
People Are The Constraint, Not Pets
Ask anyone close to this industry what keeps them awake and the answer is rarely a shortage of animals. It is vets, nurses, and the cost of keeping them. Wage inflation has been real. Retention is hard. Independent clinics often cannot offer the same progression, specialist tracks, or internal mobility.
A larger group can. That does not make labour cheap. It does make the talent problem slightly more solvable. Training pipelines, clearer career maps, and the chance to move from first-opinion work into a referral setting are practical advantages. They also cost money in the short run. Anyone buying these shares has to accept that clinician investment can cap near-term margin expansion even when volumes look healthy.
Growth that depends on scarce professionals will always look a little messier in the middle of the income statement than it does in the revenue line.
That is not a reason to walk away by itself. It is a reason to stop treating every dip in margin as a broken model. Sometimes it is just the price of keeping the people who generate the fees.
Australia Looks Like The United Kingdom Fifteen Years Ago
The UK story is mature compared with what the group is trying to build overseas. Australia still looks fragmented, independently owned, and open to a buyer that already knows how to integrate clinics without wrecking clinical culture. In three years the company has bought 57 practices with around £80 million of annual sales. That is not a side project anymore.
Does that guarantee the UK playbook will copy and paste? No. Local labour markets differ. Regulation differs. Integration can slip. I would rather see a few more years of evidence before calling Australia a carbon copy of the domestic success. Even so, the optionality is obvious. If capital can be recycled into another consolidating market at decent returns, the growth runway stretches beyond a fully built UK network.
Perhaps the most interesting aspect is timing. Management kept buying and integrating while the share price was busy discounting regulatory noise at home. That is either disciplined or stubborn, depending on your mood. Looking at the sales contribution now, it looks closer to disciplined.
| Piece of the story | What it offers | What can go wrong |
| UK first-opinion network | Resilient volume and brand density | Wage pressure and utilisation dips |
| Referral hospitals and labs | Higher ticket work kept in-house | Underused specialist capacity |
| Healthy Pet Club | Recurring fees and visit frequency | Churn if perceived value fades |
| Australia acquisitions | Fresh consolidation runway | Integration and cultural misfires |
The Regulatory Shadow And Why The Multiple Compressed
For about three years the sector lived under a competition review. Investors did what investors often do with regulatory processes. They assumed the worst remedies, marked the whole industry down, and waited. Shares in CVS Group drifted toward that low-teens earnings multiple even as the operating record stayed intact.
Now that the process is largely behind the market, the question changes. Can the group still earn attractive returns after whatever constraints remain? Can pricing, referrals, and ownership structures still support the old growth algorithm? Those are fair questions. Treating the entire franchise as damaged goods was never a precise answer.
I am wary of victory laps. Regulation can still shape advertising, ownership transparency, and how groups talk about prices. None of that is trivial. It is also not the same thing as a business that stopped compounding. The gap between those two interpretations is where the valuation argument lives.
What The Old Premium Was Actually Paying For
For a long stretch the shares sat above 20 times earnings. That was not just fashion. Buyers were paying for a bundle that is hard to find in the UK market: defensive demand, double-digit earnings growth more often than not, cash conversion that funded more clinics, and a management team that kept finding places to reinvest.
Those traits did not vanish because a review was opened. If anything, the overseas push widened the set of places capital can go. So why the cheap multiple? Fear is sticky. Once a stock becomes “the CMA name,” some funds simply wait for a clean narrative. Clean narratives take time. Charts do not always wait politely.
Businesses that can throw off resilient cash, grow at a decent clip, and reinvest at acceptable returns do not usually linger at 13 times unless something structural is broken. The burden of proof has shifted. Sceptics need to show the engine is impaired. Bulls need to show the market will care again before the cheapness disappears the other way, through slower growth rather than a rerating.
The Risks That Still Deserve A Hard Look
It would be sloppy to wave away the awkward bits. Labour inflation can keep biting. A tight market for clinicians is not a one-quarter story. If wage growth outruns fee growth for long enough, the compounding looks less elegant.
Australia still has to prove it can look like the UK over a full cycle, not just a busy acquisition window. Buying practices is the easy photograph. Embedding systems, culture, and referral flows is the unglamorous sequel.
A rerating may also take longer than impatient holders want. Markets can stay allergic to a ticker long after the original scare fades. That is annoying. It is not the same as being wrong about the cash flows.
- Watch clinician pay and vacancy rates before celebrating margin recovery
- Track like-for-like growth separately from acquired sales in Australia
- Keep an eye on subscription retention inside the pet plan
- Ask whether specialist utilisation is rising as the network densifies
- Accept that multiple expansion can lag operating progress by a year or more
None of those points kill the thesis. They stop it from becoming a slogan.
How I Think About Position Size And Time Horizon
This is not a trade you squeeze into a weekend. The argument is that a high-quality network got marked down for a sector event, kept investing through the noise, and now screens cheaper than its history without looking operationally broken. That kind of setup usually pays in years, not weeks.
I would not bet the house on a sharp rerating next quarter. I would also not pretend 13 times is a mysterious coincidence if the growth algorithm is still broadly intact. Patient capital has an edge here precisely because the story is a bit dull once you leave the regulatory headlines behind. Dull compounding is often where the money hides.
If you need income this week, look elsewhere. If you can live with wage noise and a slower path to a higher multiple, the risk and reward start to look asymmetric. Downside still exists. It just has to come from the clinics, not from a press release about an inquiry everyone already knows about.
What Would Change My Mind
A thesis needs kill switches. Mine would start with sustained like-for-like softness that cannot be explained by weather, one-off mix, or a short staffing crunch. Persistent falls in plan membership would also bother me, because that club is both a cash stream and a loyalty engine.
On the overseas side, a string of messy integrations or a sudden slowdown in available targets would shrink the growth runway. And if remaining remedies started to crimp pricing power in a visible way, the old premium multiple would deserve to stay buried.
Until those things show up in the numbers, talking about this company as if it were still trapped in 2023 feels lazy. The business moved. A lot of the valuation conversation did not.
A Practical Way To Read The Next Few Reports
Skip the poetry and watch four things. First, organic growth in the UK first-opinion estate. Second, the mix shift toward diagnostics and referrals. Third, cash conversion after maintenance spend and clinician investment. Fourth, the run-rate contribution from Australia once you strip out the thrill of deal announcements.
If those four hold up, the cheap multiple becomes harder to defend. If they wobble together, the discount is earned. That is a cleaner framework than arguing about sentiment on any given Monday.
Simple scorecard I keep in a notebook: Demand resilience Specialist capture People costs versus fees Australia integration quality Cash left after reinvestment
It is not sophisticated. It is hard to game. That is the point.
So, Should You Buy The Shares?
There is no honest one-word answer. If you believe veterinary spend stays resilient, that an integrated network still earns the right to keep more of each animal’s lifetime care, and that Australia can become more than a collection of logos, today’s price looks like an entry point rather than a value trap. If you think labour inflation will eat the model and the old premium was only ever a fashion, you wait.
My own lean is toward the first camp, with a smaller size than I would have used in a quieter year. The company looks stronger than it did when the review began. The share price still behaves as if the fog never lifted. That gap can close the slow way, through earnings, or the faster way, through a rerating. Either path can work if the clinics keep doing what they have done for the better part of two decades.
Just do not buy it because a multiple looks low in isolation. Buy it if you are comfortable owning a people-heavy healthcare network that grows by keeping clients, clinicians, and referrals inside the same fence. That is the real business. The ticker is only the wrapper.
The inquiry depressed the valuation for years. It did not stop the group from growing. If the market ever decides to focus on the second fact, today’s price may look generous in hindsight.
That is the whole case, without the romance. A defensive industry. A network that kept investing. A multiple that still remembers the scare. Whether that is enough depends on your patience more than on the next headline.
